- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 4.17 EX-4.17
- 4.26 EX-4.26
- 4.33 EX-4.33
- 4.34 EX-4.34
- 4.35 EX-4.35
- 4.36 EX-4.36
- 4.37 EX-4.37
- 4.38 EX-4.38
- 4.39 EX-4.39
- 4.40 EX-4.40
- 4.44 EX-4.44
- 4.45 EX-4.45
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15.1 EX-15.1
- 15.2 EX-15.2
- 16.1 EX-16.1
- Download Excel data file
- View Excel data file
Exhibit 15.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement on Form S-8 (No, 333-231636) pertaining to both the Mereo BioPharma Group plc 2019 Equity Incentive Plan and the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan; and |
(2) | Registration Statement on Form S-8 (No. 333-236498) pertaining to both the Mereo BioPharma Group plc 2019 Equity Incentive Plan and the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan; and |
(3) | Registration Statement on Form S-8 (No. 333-252147) pertaining to i) Mereo BioPharma Group plc 2019 Equity Incentive Plan, as amended; ii) Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan, as amended, iii) Mereo BioPharma Group plc Share Option Scheme 2016, as amended; iv) Mereo BioPharma Group plc Deferred Bonus Share Plan 2016, as amended; v) Mereo BioPharma Group plc Long Term Incentive Plan 2016, as amended and vi) Mereo BioPharma Group Share Option Scheme 2015, as amended; and |
(4) | Registration Statement on Form S-8 (No, 333-262151) pertaining to both the Mereo BioPharma Group plc 2019 Equity Incentive Plan and the Mereo BioPharma Group plc 2019 Non-Employee Equity Incentive Plan; and |
(5) | Registration Statements on Form F-3 (No. 333-249341, No. 333-239708 and No. 333-258495) of Mereo BioPharma Group plc and in the related Prospectuses; |
of our report dated March 31, 2021, with respect to the consolidated financial statements of Mereo BioPharma Group plc included in this Annual Report (Form 20-F) for the year ended December 31, 2021.
/s/ Ernst & Young LLP
London, United Kingdom
March 31, 2022